IVERIC bio, Inc. Net Change in Cash
IVERIC bio, Inc. reported Net Change in Cash of -$8.73 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-10.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2023-05-10
- IVERIC bio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$8.73M.
- IVERIC bio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2022-03-31 was -$69.58M.
- IVERIC bio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2021-03-31 was -$37.04M.
- IVERIC bio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2020-03-31 was -$17.35M.
- IVERIC bio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $214.86M, a 10.14% increase from fiscal 2021.
- IVERIC bio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2021 was $195.07M.
- IVERIC bio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2020 was -$59.33M.
- IVERIC bio, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2019 was -$5.50M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2023-03-31 | -$8.73M 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | $214.86M 10-K · filed 2023-03-01 | |||
| 2022-09-30 | -$108.35M 10-Q · filed 2022-11-04 | |||
| 2022-06-30 | -$120.33M 10-Q · filed 2022-07-26 | |||
| 2022-03-31 | -$69.58M 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $195.07M 10-K · filed 2023-03-01 | |||
| 2021-09-30 | $113.51M 10-Q · filed 2022-11-04 | |||
| 2021-06-30 | -$16.01M 10-Q · filed 2022-07-26 | |||
| 2021-03-31 | -$37.04M 10-Q · filed 2022-05-04 | |||
| 2020-12-31 | -$59.33M 10-K · filed 2023-03-01 | |||
| 2020-09-30 | -$2.88M 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | $120.04M 10-Q · filed 2021-08-04 | |||
| 2020-03-31 | -$17.35M 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | -$5.50M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | -$36.35M 10-Q · filed 2020-11-03 | |||
| 2019-06-30 | -$24.31M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | -$14.56M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | -$35.77M 10-K · filed 2021-03-04 | |||
| 2018-09-30 | -$31.76M 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | -$20.98M 10-Q · filed 2019-08-01 | |||
| 2018-03-31 | -$12.06M 10-Q · filed 2019-05-08 | |||
| 2017-12-31 | $33.04M 10-K · filed 2020-02-27 |